EGF and coronary artery disorder: PCSK9’s influence on CAD operates through multiple mechanisms, including binding to epidermal growth factor (EGF) domains on receptors, interacting with receptors in lipid rafts and cell membrane micro-domains, and modulating gene expression and protein responses involved in cardiac complications [31].